PhenoAgeAccel is associated with all-cause and cardiovascular mortality in patients with diabetes and prediabetes: A cohort study
Authors' conclusion
Higher PhenoAgeAccel is associated with increased all-cause and cardiovascular mortality in patients with diabetes and prediabetes.
Study context
- Population
- Patients with diabetes or prediabetes, NHANES 1999–2018
- Participants
- 15,939 patients
- Exposure
- PhenoAgeAccel
- Outcome
- All-cause and cardiovascular mortality
Methodological detailsNHANES 1999-2018
- NHANES 1999-2018
Main finding
As reported in the abstract
Per 1-year increase in PhenoAgeAccelEstimate (95 % CI)
5.1 % higher risk
HR (all-cause mortality) 1.051(1.046–1.057)
5.4 % increased risk
HR (CV mortality) 1.054(1.044–1.065)
Per 1-year increase in PhenoAgeAccel, as printed
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| All-cause and CV mortality by quartile | P < 0.001 |
- All-cause and CV mortality by quartile: 191.9 % higher all-cause mortality and 192.6 % higher CV mortality with Q4 (both p < 0.001)
Dose-response (restricted cubic spline (RCS))
- Linear positive associations with all-cause and CV mortality (both P-nonlinear > 0.05)
Original publication
PhenoAgeAccel is associated with all-cause and cardiovascular mortality in patients with diabetes and prediabetes: A cohort study. Diabetes Res Clin Pract. Published 12 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →